- Raw materials
- Barbiturates
- Febarbamate
Febarbamate API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Febarbamate | CAS No: 13246-02-1 | GMP-certified suppliers
A medication that acts as a central nervous system depressant and centrally acting muscle relaxant, primarily investigated for potential neuromuscular and musculoskeletal disorders.
Therapeutic categories
Product Snapshot
- Febarbamate is an oral small molecule pharmaceutical ingredient
- It is primarily investigated for use in neurological conditions such as anxiety and muscle relaxation
- The compound is currently in an experimental phase with no FDA or EMA approval
Clinical Overview
Currently, Febarbamate is designated as an experimental agent with no established clinical indication or approved therapeutic use. As such, its pharmacodynamics and detailed mechanism of action have not been conclusively defined in the literature. Generally, molecules in this class exhibit central nervous system depressant activity, often modulating neuronal excitability through interaction with gamma-aminobutyric acid (GABA) receptor systems or related pathways; however, specific receptor affinities or downstream effects for Febarbamate are not documented.
Information on absorption, distribution, metabolism, and excretion (ADME) properties for Febarbamate is not publicly available. Similarly, detailed safety or toxicity profiles have not been reported in clinical or preclinical studies, which limits understanding of its risk profile. Given its experimental status, careful consideration should be applied in any investigational use, including thorough evaluation of potential central nervous system effects and toxicity observed for related compounds.
No marketed pharmaceutical products containing Febarbamate are currently approved in major global markets. Its use is limited to research settings or investigational contexts rather than widespread clinical application.
For API procurement, critical quality attributes such as purity, identity confirmation via spectral methods, and compliance with Good Manufacturing Practices (GMP) standards should be prioritized. Sourcing from validated manufacturers with transparency regarding synthetic routes and impurity profiles is essential to support pharmacological research or development programs involving Febarbamate.
Identification & chemistry
| Generic name | Febarbamate |
|---|---|
| Molecule type | Small molecule |
| CAS | 13246-02-1 |
| UNII | 5Z48ONN38P |
| DrugBank ID | DB13303 |
Formulation & handling
- Febarbamate is a small molecule barbituric acid derivative primarily suitable for oral formulations due to its physicochemical properties.
- Low aqueous solubility (5.39e-02 g/l) suggests the need for solubilization strategies or use in solid dosage forms.
- Moderate lipophilicity (LogP 2.38) may influence absorption and distribution, requiring consideration during formulation design.
Regulatory status
Febarbamate is a type of Barbiturates
Barbiturates are a category of pharmaceutical active pharmaceutical ingredients (APIs) that have sedative, hypnotic, and anticonvulsant properties. They belong to the class of drugs called depressants, which slow down the central nervous system (CNS) activity. Barbiturates have been widely used in the medical field for their ability to induce sleep, reduce anxiety, and control seizures.
The mechanism of action of barbiturates involves enhancing the effects of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. GABA inhibits the transmission of signals between nerve cells, leading to relaxation and sedation. Barbiturates bind to specific GABA receptors, increasing the inhibitory effects of GABA and resulting in a calming effect on the CNS.
In the past, barbiturates were commonly prescribed for insomnia, anxiety disorders, and epilepsy. However, their use has decreased significantly due to the emergence of safer and more effective alternatives with fewer side effects. Nonetheless, barbiturates are still utilized in certain medical situations, such as anesthesia induction, emergency seizure control, and in some cases of refractory epilepsy.
Despite their therapeutic benefits, barbiturates carry potential risks and side effects. They can cause drowsiness, impaired coordination, and dependence when used for extended periods. Overdose of barbiturates can be life-threatening, leading to respiratory depression and coma.
In conclusion, barbiturates are a class of API widely known for their sedative, hypnotic, and anticonvulsant properties. While their use has diminished over time, they remain important in specific medical contexts. Proper caution and medical supervision are crucial when using barbiturates to ensure safety and efficacy.
